Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - License Agreements - Additional Information (Details)

v3.24.1.1.u2
Commitments and Contingencies - License Agreements - Additional Information (Details) - TMRC - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2021
May 31, 2021
May 31, 2016
Sep. 30, 2015
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Up-front license fee       $ 1,000,000      
Payment of up-front license fee     $ 500,000 500,000      
Payments per indication due upon the successful achievement of clinical and regulatory milestones       $ 13,000,000      
Payments made upon achievement of development milestone $ 1,000,000 $ 2,000,000         $ 1,000,000
Fees incurred under supply management agreement         $ 0 $ 0